Last reviewed · How we verify
Placebo anacetrapib
Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor, which increases HDL cholesterol and reduces LDL cholesterol.
Anacetrapib is a cholesterol ester transfer protein (CETP) inhibitor, which increases HDL cholesterol and reduces LDL cholesterol. Used for Reduction of cardiovascular events in patients with atherosclerotic cardiovascular disease.
At a glance
| Generic name | Placebo anacetrapib |
|---|---|
| Sponsor | University of Oxford |
| Drug class | CETP inhibitor |
| Target | cholesterol ester transfer protein (CETP) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting CETP, anacetrapib increases the levels of high-density lipoprotein (HDL) cholesterol and decreases the levels of low-density lipoprotein (LDL) cholesterol. This mechanism is thought to reduce the risk of cardiovascular events.
Approved indications
- Reduction of cardiovascular events in patients with atherosclerotic cardiovascular disease
Common side effects
- Musculoskeletal pain
- Back pain
- Arthralgia
Key clinical trials
- REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (PHASE3)
- The Effect of Anacetrapib on Vascular Function and Arterial Stiffness
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) (PHASE3)
- Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) (PHASE3)
- Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) (PHASE3)
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) (PHASE3)
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) (PHASE3)
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |